JPRN-C000000330已完成2 期
Peripheral blood mononuclear cell therapy in PAD patients with intermittent claudication randamized trial - PB-MNC therapy (PERTINENT) trial
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine0 个研究点目标入组 60 人开始时间: 2006年2月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with malignant diseases, severe diabetic retinopathy, or severe renal failure.
研究者
相似试验
已完成
不适用
Peripheral blood mononuclear cell therapy in PAD patientsPeripheral artery disease due to collagen diseaseJPRN-UMIN000000764Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine20
未知
不适用
Peripheral blood mononuclear cell implantation for patients with severe ischemic heart diseaseSevere ischemic heart diseaseJPRN-UMIN000001289Department of Cardiovascular Science and Medicine,Graduate School of Medicine,Chiba University30
已完成
1 期
Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver CirrhosisLiver CirrhosisNCT01503749Seoul National University Hospital9
已完成
1 期
PBMC-therapy and treatment of recurrent implantation failure (RIF)IRCT2017081227520N8Stem Cell And Regenerative Medicine Institute,Tabriz University of Medical Sciences100
进行中（未招募）
不适用
Immunotherapy by autologous peripheral blood mononuclear cells and GM-CSF for hepatocellular carcinoma undergoing radiofrequency thermal ablation - HCC thermal ablation and immunotherapy combined treatmentpatients with hepatocellular carcinomaMedDRA version: 9.1Level: LLTClassification code 10059319Term: Hepatic cancer stage IIEUCTR2008-003925-17-ITAZIENDA OSPEDALIERA DI PARMA